Orforglipron: The Daily Weight Loss Pill That Produced Up to 14.7% Body Weight Reduction in 36 Weeks

In this phase 2 NEJM trial, the oral GLP-1 pill orforglipron produced up to 14.7% body weight loss at 36 weeks in adults with obesity — compared to just 2.3% with placebo. At the highest dose (45 mg), 75% of participants lost at least 10% of their body weight. The drug also improved all prespecified cardiometabolic measures. Gastrointestinal side effects were the main issue, causing 10-17% of participants to discontinue, but these were mostly mild-to-moderate and occurred during the dose ramp-up period.

This was a phase 2, randomized, double-blind, placebo-controlled trial. 272 adults with obesity (mean BMI 37.9, mean weight 108.7 kg) or overweight with weight-related conditions — and without diabetes — were randomized to one of four orforglipron doses (12, 24, 36, or 45 mg) or placebo, taken orally once daily for 36 weeks. The primary endpoint was percentage change in body weight at week 26, with week 36 as a secondary endpoint.

This is a landmark trial published in the New England Journal of Medicine — one of the first rigorous demonstrations that an oral, non-peptide GLP-1 drug can produce weight loss approaching what injectable semaglutide achieves. Because orforglipron is a small molecule (not a peptide), it doesn't need special absorption enhancers and can be taken as a simple daily pill. If confirmed in phase 3 trials, it could dramatically expand access to GLP-1-based weight loss treatment by removing the injection barrier.

Injectable GLP-1 drugs have transformed obesity treatment, but needles remain a major barrier for many patients. Oral semaglutide (Rybelsus) exists but requires special absorption technology and fasting restrictions. Orforglipron is different — it's a small molecule, not a peptide, so it doesn't need those workarounds. This NEJM trial put orforglipron on the map as a potential game-changer: a simple daily pill that could bring GLP-1-level weight loss to the mass market. Eli Lilly has since advanced it to phase 3 trials.

This is a phase 2 trial with only 272 participants — large enough to establish efficacy signals but too small to detect rare adverse events. The 36-week duration doesn't address long-term safety or whether weight loss is maintained. Participants with diabetes were excluded, so results may not generalize to that population. The 10-17% discontinuation rate due to side effects across dose groups is notable.